Health-care companies were more or less flat amid mixed earnings.
Sales of Novo Nordisk's blockbuster obesity treatment Wegovy more than doubled in the first quarter as its manufacturer races to make more of the drug to meet surging demand.
Shares of biotech company Moderna rallied after the company reported a narrower-than-expected first-quarter loss and took steps toward launching an RSV vaccine in the U.S. later this year.
Pharmaceutical giant Novartis said it will pay up to $1.75 billion for a U.S. biotech focused on cancer. Asia's factory activity weakened slightly in April, with output growth cooling and employment dropping in a sign of fragile confidence among manufacturers.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
05-02-24 1712ET
